Does Myriad alter the patentability of natural products?

Managing Intellectual Property
March 2014

Robert Schwartz and Leslie Kushner examine whether the ruling of the Supreme Court case, Association of Molecular Pathology v. Myriad Genetics, Inc. , — finding that a naturally occurring DNA sequence is a product of nature that is not patent eligible — is narrowly applicable only to nucleic acids or will be broadly interpreted to apply to all naturally occurring biomolecules.

View Attachment (PDF)